LONDON--(BUSINESS WIRE)--The global neuroendocrine tumors therapeutics market is highly concentrated. Because of the high investment required for drug development and commercialization, vendors are focusing on entering into partnerships with other companies. To help clients improve their revenue share, this research report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. This industry research report also presents a competitive analysis of the market by type (somatostatin analogs, targeted therapies, other therapies) and by geography (Asia, Europe, North America, ROW).
Competitive vendor landscape
The global neuroendocrine tumors therapeutics is highly competitive with major vendors such as F. Hoffmann-La Roche Ltd, Ipsen Pharma, Merck & Co., Inc, Novartis AG, and Pfizer Inc. based on their product/service offerings.
“To gain higher market shares, companies as a key strategy are involved in acquisitions and partnerships along with effective product launches. Leading corporations are aggressively pursuing to enhance their capabilities to gain a competitive edge through joint ventures, MoUs, and agreements or acquisitions,” says a senior analyst at Technavio.
Top five neuroendocrine tumors therapeutics vendors
F. Hoffmann-La Roche Ltd
The company provides in-vitro diagnostics and drugs for cancer and transplantation and specializes in medicines for chronic diseases, infectious diseases, and microbiology. The company operates in two segments, Pharmaceuticals, and Diagnostics. The company’s offerings include XELODA, which is also known as capecitabine tablets. It is available in two strengths, 150 mg, and 500 mg.
Ipsen Pharma runs its operations through two segments Specialty Care and Consumer Healthcare. Its offerings include SOMATULINE DEPOT, which is a lanreotide injection, that is available in three strengths: 60 mg, 90 mg, and 120 mg.
Merck & Co.
Merck & Co. runs its operations through three segments, Pharmaceutical, Animal Health, and Other. The company offers a medicine called TEMODAR, under the pharmaceutical segment, which is available as capsules in 5 mg, 20 mg, 100 mg, and 250 mg doses.
The company runs its operations through three segments, Innovative Medicines, Sandoz, and Alcon. The company’s offerings include AFINITOR, LUTATHERA, and Sandostatin LAR Depot.
Pfizer Inc. runs its operations through two segments, Innovative Health, and Essential Health. The company’s offerings include BAVENCIO and SUTENT.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report, including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Japanese Encephalitis Vaccines Market 2019-2023 - The market research study identifies Bharat Biotech Ltd., Biological E. Ltd., Green Cross Corp., Sanofi, Valneva SE.as the leading players in the global Japanese encephalitis vaccines market.
- Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 - The market research study identifies Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Novartis AG, and Pfizer Inc. as the leading players in the global obsessive-compulsive disorder drugs market.
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.